Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Q2 2024 Earnings Presentation
15 slides from Optomed Oyj Class A's earnings presentation, Aug 8, 2024
Slide 1: Optomed Q2 2024
Optomed Q2 2024 8th August 2024 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights
Highlights 1. 2. 3. Optomed Aurora- Joint venture in China Cash position AEYE sales started with Zhongbao Fund strengthened
Slide 3: Q2-2024 Key Figures
Q2-2024 Key Figures OUR TOPLINE DECLINED DUE TO SLOW QUARTER IN THE DEVICES SEGMENT Q2/2024 Q2/2023 Change Revenue 3,505 3,744 -6.4% Gross profit 2,450 2,486 -1.5% Gross margin 69.9% 66.4% 35pps Adjusted EBITDA -802 -462 -73.4% Adjusted EBITDA margin -22.9% -12.4% -105pps Net profit / loss -1,793 -1
Slide 4: H1-2024 Key Figures
H1-2024 Key Figures OUR H1 TOPLINE IS DOWN SLIGHTLY AGAINST THE COMPARISON PERIOD H1/2024 H1/2023 Change Revenue 6,832 7,222 -5.4% Gross profit 4,663 4,962 -6.0% Gross margin 68.3% 68.7% -5pps Adjusted EBITDA -1,450 -976 -48.6% Adjusted EBITDA margin -21.2% -13.5% -77pps Net profit / loss -2,883 -2,
Slide 5: Developments in two key markets
Developments in two key markets MAJOR STRATEGIC DEVELOPMENTS IN BOTH USA AND CHINA • Optomed Aurora with AEYE- DS AI received FDA • Joint venture agreement clearance signed with Zhongbao Fund • The clinical results were 92% • The business model will be - 93% sensitivity, 89% - 94% a recurring revenu
Slide 6: Segment highlights
Segment highlights OPT@MED
Slide 7: Devices Segment Q2-2024
Devices Segment Q2-2024 TOPLINE DOWN BY EUR 200K Q2/2024 Q2/2023 Change Revenue declined by EUR 200k 1. due to softness of the global distributor sales and OEM channel Revenue 1,073 1,273 -15.7% Gross margin was 64.8 (53.0) Gross profit 695 674 3.2% 2. percent and EBITDA -686 (-217) thousand Gross m
Slide 8: Software Segment Q2-2024
Software Segment Q2-2024 SOFTWARE REVENUE WAS REMAINED ON THE SAME LEVEL Q2/2024 Q2/2023 Change Software segment revenue was 1. stable, and EBITDA decreased Revenue 2,432 2,471 -1.6% Optomed won a contract to provide Gross profit 1,746 1,812 -3.7% 2. non-healthcare development services to a Finnish
Slide 9: Cash Flow Q2-2024
Cash Flow Q2-2024 CASH POSITION STRENGHTENED Q2 2024 Q2 2023 Loss for the financial year -1,793 -1,314 Cash flows before change • Share issue of EUR 7.9 in net working capital -688 -479 million completed in Q2-2024 Change in net working capital 165 52 • This boosted the cash Cash flows before financ
Slide 10: Summary
Summary • Major strategic developments in USA and China • Cash position strengthened • We are well positioned for the next phase of growth
Slide 11: Appendix
Appendix OPT@MED
Slide 12: Devices Segment H1-2024
Devices Segment H1-2024 H1/2024 H1/2023 Change Revenue 1,963 2,161 -9.2% Gross profit 1,211 1,233 -1.7% Gross margin 61.7 % 57.0 % 82pps EBITDA -1,047 -643 -62.8% EBITDA margin -53.3 % -29.8 % -792pps
Slide 13: Software Segment H1-2024
Software Segment H1-2024 H1/2024 H1/2023 Change Revenue 4,869 5,061 -3.8% Gross profit 3,442 3,729 -7.7% Gross margin 70.7 % 73.7 % -41pps EBITDA 982 1,368 -28.2% EBITDA margin 20.2 % 27.0 % -254pps
Slide 14: Cash Flow H1-2024
Cash Flow H1-2024 H1 2024 H1 2023 Loss for the financial year -2,883 -2,471 Cash flows before change in net working capital -1,283 -980 Change in net working capital 296 105 Cash flows before finance items -987 -875 Cash flows from finance items -84 -38 Net cash from operating activities -1,071 -913
Slide 15: Balance Sheet
Balance Sheet 30 June 2024 30 June 2023 • Equity ratio of 74.9 (63.6) ASSETS percent Goodwill 4,256 4,256 Development costs 8,126 7,200 Other intangible assets 1,586 1,918 • Total borrowings of EUR Total intangible assets 13,969 13,374 2.9 (4.8) million Total tangible assets 630 769 Total non-curren